A project to investigate the actual status of biomarker testing in unresectable advanced or recurrent non-small cell lung cancer (REVEAL)(WJOG15421L)

A project to investigate the actual status of biomarker testing in unresectable advanced or recurrent non-small cell lung cancer (REVEAL)(WJOG15421L) - A project to investigate the actual status of biomarker testing in unresectable advanced or recurrent non-small cell lung cancer

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000046079

Enrollment

1500

Registered

2022-01-04

Start date

2022-01-04

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Non-small cell lung cancer

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1) Histologic or cytologic evidence of non-small cell lung cancer (advanced or recurrent) from July 1st 2020 to June 30th 2021. 2) Written informed consent (opt-out is permitted) 3) Age >= 20 years at diagnosis

Exclusion criteria

Exclusion criteria: None

Design outcomes

Primary

Measure	Time frame
Identification of biomarker test status before initial treatment for advanced/recurrent non-small cell lung cancer	—

Secondary

Measure	Time frame
1. Proportion of patients receiving relevant targeted therapy based on each biomarker 2. Objective response rate 3. Time to treatment failure 4. Overall survival 5. The rate of patients receiving second-line therapy after disease progression for first-line therapy	—

Countries

Japan

Contacts

Public ContactShinichiro Nakamura

West Japan Oncology Group WJOG datacenter

datacenter@wjog.jp06-6633-7400

Outcome results